A Phase 1/2, Randomized, Single-blind, Placebo-Controlled, Single Ascending Dose and Multiple Dose, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Subcutaneously Administered ALN-AAT in Healthy Adult Subjects and Patients With ZZ Type Alpha-1 Antitrypsin Deficiency Liver Disease.

Trial Profile

A Phase 1/2, Randomized, Single-blind, Placebo-Controlled, Single Ascending Dose and Multiple Dose, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Subcutaneously Administered ALN-AAT in Healthy Adult Subjects and Patients With ZZ Type Alpha-1 Antitrypsin Deficiency Liver Disease.

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 10 Jun 2017

At a glance

  • Drugs ALN AAT (Primary)
  • Indications Alpha 1-antitrypsin deficiency
  • Focus Adverse reactions; First in man
  • Sponsors Alnylam Pharmaceuticals
  • Most Recent Events

    • 02 Jun 2017 Planned End Date changed from 1 Apr 2017 to 1 Nov 2017.
    • 29 Sep 2016 Results presented at the 12th Annual Meeting of the Oligonucleotide Therapeutics Society (OTS) 2016, according to an Alnylam Pharmaceuticals media release.
    • 28 Sep 2016 Results published in an Alnylam Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top